SONN News & Events

Sonnet BioTherapeutics announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies and Rorschach I at its special meeting of stockholders. The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.

Sonnet BioTherapeutics Holdings is collaborating with Spanios on a non-clinical study using New Alternate Methodologies-based patient-derived tumoroid platforms that emulate the tumor microenvironment ex vivo to evaluate the effect of SON-1010 in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers. This study utilizes Spanios' advanced patient-derived tumoroid COMPASS platform, which is engineered to closely replicate the TME, along with physiological oxygenation that can influence cancer progression and treatment response. In contrast to conventional preclinical models-often based on animal testing and less representative of human biology-patient-derived tumoroids preserve the distinct genetic and environmental attributes of individual tumors. By replicating the different pH and oxygen concentrations ex-vivo, using our COMPASS platform with our NAM-based methodology, we seek to enhance the understanding of SON-1010's efficacy against cancer cells. This approach is anticipated to yield more accurate and dependable predictions regarding the clinical performance of SON-1010 therapy. Through the integration of these innovative techniques, Sonnet intends to expedite the development of effective therapies for multiple rare and difficult-to-treat cancers, ultimately providing new options for patients with limited treatment paradigms.

Sonnet BioTherapeutics announced the release of a Virtual Investor "What This Means" segment. As part of the segment, Dr. Richard Kenney, CMO discussed its recent update on its SB221 clinical trial including that enrollment of the expansion group using the highest maintenance dose from the monotherapy study has been completed, two of the three patients in the E6 does escalation cohort had partial responses, and this provides an opportunity to study the safety of the combination in a larger population. Sonnet expects to get a preliminary efficacy readout later this year. Additionally, Dr. Kenney discussed adding an E7 cohort using a maintenance dose of 1500 ng/kg to study its safety and effectiveness before proceeding to the randomized Phase 2a portion next year, which will evaluate PROC patients at one of the two highest doses compared to the standard of care, following the dose recommendation from the Safety Review Committee.